WHO Scientific Working Group on monitoring and management of bacterial resistance to antimicrobial agents. by Tenover, F. C. & Hughes, J. M.
WHO Scientific Working Group
on Monitoring and Management
of Bacterial Resistance to
Antimicrobial Agents
Antibacterial resistance is a global clinical and
public health problem that has emerged with alarm-
ing rapidity in recent years and undoubtedly will
increase in the near future. Resistant bacteria do not
respect national borders, and developments in the
remote locations can have an impact throughout the
world. Resistance is a problem in the community as
well as in health care settings, where transmission
of bacteria is greatly amplified, in both developed
and developing countries. Because multiple drug
resistance is a growing problem, physicians are now
confronted with infections for which there is no effec-
tive therapy. The morbidity, mortality, and financial
costs of such infections pose an increasing burden for
health care systems worldwide, but especially in
countries with limited resources.
The Division of Communicable Diseases at the
World Health Organization, Geneva, Switzerland,
recently convened a Scientific Working Group to
address the problem of drug-resistant bacterial in-
fections. From November 29 to December 2, 1994,
participants from 23 countries reviewed and dis-
cussed scientific data on the nature and costs of drug
resistance; recent national and global trends; ap-
proaches to limiting the emergence and spread of
resistance in community and institutional settings;
and strategies to strengthen local, national, and
global surveillance. Participants included repre-
sentatives from clinical medicine, public health, the
clinical laboratory, and the biomedical research
arenas and from the pharmaceutical industry.
The Working Group formulated a series of recom-
mendations to address these issues at local, national,
and international levels. The recommendations
placed emphasis on enhanced surveillance of drug
resistance through usage of WHONET software, in-
creased monitoring and improved usage of antimi-
crobial drugs in human, veterinary, and animal
husbandry settings, improved laboratory diagnostic
capacity, standardization and quality control of labo-
ratory methodology, professional and public educa-
tion, development of new drugs and assessment of
alternative therapeutic modalities, assessment of
vaccine development and delivery priorities related
to antimicrobial resistance, better implementation
of infection control measures, and evaluation of pre-
vention strategies. 
The Working Group plans to release its final re-
port in the spring.
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